Sorafenib Online



How and where to order Nexavar (Sorafenib) 200 mg tablets online on About Liver Tumors website:

Shop:MEDICINES STORE
Stores:PHARMA DOCTOR
Prices:from $165.00 per pack (30 tablets)
Discount:10% coupon: MSD10
Forms:Nexavar (Sorafenib) 200 mg tablets
Quantity:30, 60, 90, 120 pills
Type:Sorafenib brand, Soranib brand, Nexavar generic
Payment:Visa, Mastercard, AmEx, E-Check (ACH), Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Sorafenib (trade names include Nexavar, Sorafenat, Soranib, Soranix) is an anti-cancer drug from protein kinase inhibitors pharmacological group. This medication is used for the treatment of advanced primary liver cancer (hepatocellular carcinoma), primary kidney cancer (advanced renal cell carcinoma, advanced renal cancer), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. It is in researcj studies for the treatment of lung, brain (recurrent glioblastoma), ovarian cancer, desmoid tumor (aggressive fibromatosis). It works by inhibiting protein kinases enzymes in cancer cells.


Nexavar (Sorafenib Tosylate) tablets


Related medications:

  • Acalabrutinib (Calquence)
  • Binimetinib (Mektovi)
  • Cediranib (Recentin)
  • Ceritinib (Zykadia)
  • Cobimetinib (Cotellic)
  • Dacomitinib (Vizimpro)
  • Dasatinib (Sprycel)
  • Erlotinib (Tarceva)
  • Exemestane (Exemestano)
  • Gilteritinib (Xospata)
  • Lorlatinib (Lorbrena)
  • Masitinib (Masivet)
  • Osimertinib (Tagrisso)
  • Ruxolitinib (Jakafi)
  • Temsirolimus (Torisel)
  • Trametinib (Mekinist)
  • Vandetanib (Caprelsa)
  • Vemurafenib (Zelboraf)


    Pharmacological and medical categories:

  • Angiogenesis inhibitors
  • Anti cancer drugs
  • Anti tumor medicines
  • Cytostatic agents
  • Medications for the treatment of liver tumors
  • Tyrosine kinase inhibitors


    ATC codes:

  • L - Antineoplastic and immunomodulating agents
  • L01 - Antineoplastic agents
  • L01X - Other antineoplastic agents
  • L01XE - Protein kinase inhibitors
  • L01XE05 - Sorafenib


    ICD-10 codes:

  • Malignant neoplasm of liver and intrahepatic bile ducts - C22
  • Liver cell carcinoma - C22.0
  • Malignant neoplasm of bronchus and lung - C34
  • Malignant neoplasm of ovary - C56
  • Malignant neoplasm of kidney, except renal pelvis - C64
  • Malignant neoplasm of brain - C71
  • Malignant neoplasm of thyroid gland - C73
  • Neoplasm of uncertain behavior of other and unspecified sites - D48
  • Fibroblastic disorders - M72


    Indications and usage:

    Nexavar (Sorafenib Tosylate) is a kinase inhibitor indicated for the treatment of:

  • Unresectable hepatocellular carcinoma
  • Advanced renal cell carcinoma
  • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment


    Dosage and administration:

  • 400 mg (2 tablets) orally twice daily without food.
  • Treatment interruption and/or dose reduction may be needed to manage adverse reactions.


    Overdosage:

    There is no specific treatment for sorafenib overdose. The highest dose of Nexavar studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals. In cases of suspected overdose, sorafenib should be withheld and supportive care instituted.


    Dosage forms and strengths:

    Nexavar (Sorafenib Tosylate) 200 mg oral tablets.


    Contraindications:

  • Sorafenib is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of Nexavar.
  • This drug in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.


    Warnings and precautions:

  • Cardiovascular Events: Consider temporary or permanent discontinuation of Nexavar.
  • Bleeding: Discontinue Nexavar if needed.
  • Hypertension: Monitor blood pressure weekly during the first 6 weeks and periodically thereafter.
  • Dermatologic Toxicities: Interrupt and/or decrease dose. Discontinue for severe or persistent reactions, or if Stevens-Johnson syndrome and toxic epidermal necrolysis is suspected.
  • Gastrointestinal Perforation: Discontinue Nexavar.
  • QT Prolongation: Monitor electrocardiograms and electrolytes inpatients at increased risk for ventricular arrhythmias.
  • Drug-Induced Liver Injury: Monitor liver function tests regularly; discontinue for unexplained transaminase elevations.
  • Embryo-Fetal Toxicity: Sorafenib may cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
  • Impairment of TSH suppression in DTC: Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer.


    Adverse reactions, side effects:

    The most common adverse reactions ( >= 20%) for Nexavar tablets are diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pains, hypertension, and hemorrhage.


    Drug interactions:

    Avoid strong CYP3A4 inducers.


    Use in specific populations:

  • Lactation: Advise women not to breastfeed.
  • Females and Males of Reproductive Potential: Verify pregnancy status prior to initiation of Nexavar (Sorafenib Tosylate) 200 mg tablets,


    Pregnancy categories:

  • D - Australia
  • D - United States (Positive evidence of risk)


    Salts and other forms:

  • Sorafenib Base
  • Sorafenib Tosylate


    Synonyms, international and chemical names:

  • Sorafenibi
  • Sorafenibum
  • Sorafeniib


    Brands, generics, trade names:

  • Nexavar - Bayer, Onyx Pharmaceuticals
  • Sorafenat - Natco Pharma
  • Soranib - Cipla
  • Soranix - Beacon Pharmaceuticals


    References:

  • Sorafenib main article on Wikipedia: https://en.wikipedia.org/wiki/Sorafenib
  • Sorafenib compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Sorafenib
  • Sorafenib Tosylate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Sorafenib-tosylate
  • Sorafenib on DrugBank: https://www.drugbank.ca/drugs/DB00398
  • Sorafenib Tosylate on DrugBank: https://www.drugbank.ca/salts/DBSALT000165
  • Sorafenib FAQ on MedlinePlus (revised 02/15/2019): https://medlineplus.gov/druginfo/meds/a607051.html
  • Nexavar (Sorafenib Tosylate) film-coated tablets drug label info on DailyMed (revised July 9, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Sorafenib for sale on Pharma Doctor: https://pharma-doctor.com/sorafenib.html
  • Nexavar (Sorafenib Tosylate) tablets for oral use official prescribing information from the U.S. FDA (revised 12/2018): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Nexavar (Sorafenib Tosylate) information from Bayer pharmaceutical company: https://www.bayer.com/en/google-search.aspx?query=nexavar
  • Nexavar (Sorafenib Tosylate) tablets official website (for U.S. visitors only): https://www.nexavar-us.com/
  • Nexavar (Sorafenib Tosylate) tablets official website for healthcare professionals (for U.S. visitors only): https://www.hcp.nexavar-us.com/
  • Nexavar (Sorafenib Tosylate) 200 mg film-coated tablets package information leaflet Medicines.org.uk (revised 09/2019): https://www.medicines.org.uk/emc/files/pil.226.pdf
  • Sorafenat (Sorafenib, Nexavar generic) 200 mg tablets from Natco Pharma Ltd prescribing information on Practo: https://www.practo.com/medicine-info/sorafenat-tablet-49138
  • Soranib (Sorafenib Tosylate) 200 mg film-coated tablets prescribing information from Cipla pharmaceutical company (revised December 2017): https://www.ciplamed.com/content/soranib-tablets

    Revised: June 2021



    Home | Disclaimer | Privacy Policy | The Liver | Treatment Options | FAQs | Contact Us

    Copyright © 2003 - 2021 About Liver Tumors. All rights reserved.